Revolution Medicines (RVMD) Corporate presentation summary

Mission and strategic focus

• Aims to revolutionize treatment for RAS-addicted cancers by developing innovative, targeted medicines.

• Pioneering a class of RAS(ON) inhibitor drug candidates targeting oncogenic drivers in life-threatening cancers.

• RMC-6236 is a multi-selective RAS(ON) inhibitor in a global Phase 3 study for 2L metastatic PDAC; monotherapy and combination studies ongoing.

• Clinical development underway for mutant-selective RAS(ON) inhibitors RMC-6291 (G12C) and RMC-9805 (G12D), with encouraging initial proof-of-concept.

RAS(ON) inhibitor portfolio and clinical progress

• RAS(ON) inhibitors designed to target a significant number of human cancers, including lung, colorectal, and pancreatic cancers.

• RMC-6236 shows compelling PFS (8.5 months) and OS (14.5 months) in 2L PDAC patients with RAS mutations.

• RMC-6291 demonstrates antitumor activity in NSCLC and CRC, including in patients previously treated with KRAS(OFF) inhibitors.

• RMC-9805 shows promising initial clinical profile in KRAS G12D PDAC, with 30% ORR and 80% DCR at 1200 mg daily.

Clinical development in pancreatic cancer (PDAC)

• PDAC is highly RAS-driven, with over 90% of patients harboring RAS mutations and a 5-year survival rate of just 3%.

• RMC-6236 demonstrated a manageable safety profile and high dose intensity, with most adverse events being Grade 1-2.

• Ongoing global Phase 3 RASolute 302 study compares RMC-6236 to standard chemotherapy in 2L metastatic PDAC.

• Plans underway for Phase 3 study of RMC-6236 in 1L metastatic PDAC.